-
Expansion of Contract Development and Manufacturing Organization (CDMO) Services to Antibody Drug Development and Manufacturing（2024/10/08）
（474KB）
-
Business Collaboration Agreement with Noile-Immune Biotech Inc. to develop the CAR-T Products for Solid Tumors（2024/09/25）
（470KB）
- Takara Bio announces the business partnership with Gap Junction Therapeutics to develop AAV gene therapy for hereditary hearing loss（2024/06/18）
- Takara Bio Announces Presentation of Advances in Gene and Cell Research at ASGCT 2024 (2024/05/02)
- Takara Bio Announces Publication of Results from NY-ESO-1・siTCR™ Gene Therapy Study in Clinical Cancer Research（2023/10/5）
- Takara Bio Announces Presentation of Comparability Studies for CD19 JAK/STAT CAR-T Cell Technology Transfer (2023/10/03)
- Takara Bio Announces Poster Presentation of Data from Clinical Trial of NY-ESO-1・siTCR™ Gene Therapy at ASCO2023 （2023/05/29）
- Takara Bio Announces Initiation of Clinical Trial for Next-Generation CAR-T therapy （2023/04/03）
-
Takara Bio Announces Transfer of SAKIGAKE and Orphan Designations for NY-ESO-1/siTCR™ Gene Therapy Product（2023/01/24）
（228KB）
- Announcement of Termination of Co-Development and Exclusive Marketing Agreements with Otsuka Pharmaceutical Co., Ltd. for NY-ESO-1 siTCR™ gene therapy candidate (2022/11/10)
- Takara Bio to Present Clinical Data from Investigator-Initiated Trial in Canada of NY-ESO-1 siTCR™ Gene Therapy at ASCO2022（2022/06/01）
- Announcement of Termination of Co-Development and Exclusive Marketing Agreements with Otsuka Pharmaceutical Co., Ltd. for Oncolytic virus HF10 and CD19-targeted CAR Gene Therapies（2021/11/09）
- Clinical program for NY-ESO-1 siTCR™ gene therapy candidate receives designation in Japan as Orphan Regenerative Medicine（2020/06/24）
